Sebela Pharmaceuticals® Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD
Press Releases
Sebela Pharmaceuticals  
April 23, 2025

Sebela Pharmaceuticals® Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD

Tegoprazan proves to be faster acting and more effective than a proton pump inhibitor (PPI) in the healing of erosive esophagitis (EE).Met all primary and secondary endpoints in healing phase

avatar profile Olean Times Herald

Olean Times Herald


Local & Social